Mayukh Sukhatme Sells 1,018,995 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 1,018,995 shares of the firm’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the completion of the transaction, the insider directly owned 20,267,429 shares of the company’s stock, valued at approximately $440,005,883.59. This represents a 4.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Monday, December 29th, Mayukh Sukhatme sold 311,873 shares of Roivant Sciences stock. The shares were sold at an average price of $21.74, for a total transaction of $6,780,119.02.
• On Wednesday, December 17th, Mayukh Sukhatme sold 26,831 shares of Roivant Sciences stock. The shares were sold at an average price of $23.09, for a total value of $619,527.79.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $21.70 on Friday. The business has a fifty day moving average of $20.87 and a 200 day moving average of $15.75. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $23.47. The firm has a market capitalization of $15.09 billion, a price-to-earnings ratio of -38.75 and a beta of 1.22.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on ROIV shares. JPMorgan Chase & Co. increased their price target on shares of Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Thursday, September 18th. Weiss Ratings raised shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. The Goldman Sachs Group increased their price objective on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Guggenheim restated a “buy” rating and set a $28.00 target price on shares of Roivant Sciences in a research report on Thursday, December 18th. Finally, Jefferies Financial Group increased their price target on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.19.

Institutional Trading of Roivant Sciences

A number of hedge funds have recently added to or reduced their stakes in ROIV. Jones Financial Companies Lllp increased its holdings in Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after buying an additional 1,148 shares in the last quarter. Allworth Financial LP grew its position in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the period. Bessemer Group Inc. increased its stake in shares of Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. CWM LLC raised its holdings in Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after purchasing an additional 920 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in Roivant Sciences by 94.8% during the first quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock worth $46,000 after purchasing an additional 2,233 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.